First Analysis
http://www.firstanalysis.com/index.asp?PID=16First Analysis is an investment organization specializing in private equity, venture capital, investment banking, and equity research. The sectors in the firm’s coverage universe include outsourced services, IT products and services, and chemistry-enabled businesses. First Analysis was founded in 1981.
View Older Stories View More Recent Stories
-
Bespoke Partners Posts Massive Growth, Hits Key Milestones
-
COPILOT Receives New Strategic Investment from QHP Capital
-
QHP Capital Invests in COPILOT
-
New Analysis Finds 30% of Chemical Safety Data Sheets Tested Include Inaccurate Hazard Warnings, Put Workers at Risk
-
New Analysis Finds 30% of Chemical Safety Data Sheets Tested Include Inaccurate Hazard Warnings, Put Workers at Risk
-
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hemato
-
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022
-
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
-
New Study Finds Higher Prevalence of Age-Related Macular Degeneration (AMD) Cases than Previously Determined and a High Degree of County Variation
-
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual
-
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
-
Profound Improvement for Pancreatic Cancer Patients Using CivaSheet®, a New Radiation Device
-
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
-
Drive My Way Closes $4.4 Million Series A Financing Round
-
Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic
-
Castle Biosciences Inc. (CSTL) Presents New Data Demonstrating Impact of DecisionDx-SCC Test Results on Management of Medicare-Eligible Patients with cSCC and One or More Risk Factors
-
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Ri
-
Premia Spine’s TOPS™ Facet Replacement Demonstrates Significant Improvement in All Patient-Reported Outcome Measures in FDA Trial
-
CoolR Group raises $10 million to accelerate automated ordering globally
-
Truveta Announces Collaboration with Boston Scientific to Advance Post-Procedure Patient Insights and Help Address Healthcare Disparities
-
Truveta Announces Collaboration with Boston Scientific to Advance Post-Procedure Patient Insights and Help Address Healthcare Disparities
-
OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results
-
Intellia Therapeutics (NTLA) Reports Positive Interim Data for NTLA-2002
-
Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
-
Gilead's Trodelvy extends breast cancer survival by 3.2 months -study
-
OSE Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer after Failure to Immune Checkpoint Inhibitors at ESMO Congress 2
-
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
-
Mycovia Pharmaceuticals Announces Presentation of Topline Results from Two Studies Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) at the 2022
-
Payment Integrity Leader ClaimLogiq Acquires NLP Pioneer SyTrue
-
EdgeIQ Raises $8.5 Million to Fuel Its Mission of Growing the Connected Product Economy
-
Mirum Pharmaceuticals (MIRM) Reports New Data at The International Liver Congress of the European Association for the Study of the Liver
-
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
-
Vertex Pharma (VRTX) to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at ECFS
-
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
-
Gilead drug modestly delays breast cancer progression in late-stage trial
-
Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL® (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice
-
Study from The Advertising Coalition Finds Advertising Drives $7.1 Trillion in US Sales
-
RedHill Presents New Talicia® Data Analyses at DDW 2022
-
Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
-
End Drug Shortages Alliance Releases Market Assessment for Drugs Impacted by Manufacturing Plant Closure
-
Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
-
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
-
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer
-
Zambon to present data on lung transplantation trends and survival rates in Europe at ISHLT 2022
-
New meta-analysis with Diamyd® published in scientific journal
-
Fortress Information Security Receives $125 Million Strategic Investment from Goldman Sachs Asset Management
-
TG Therapeutics (TGTX) Voluntarily Withdraws BLA/sNDA for U2 to Treat Patients with CLL and SLL
-
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
-
Gail Mahady Receives ABC Fredi Kronenberg Excellence in Research and Education in Botanicals for Women’s Health Award
-
Gail Mahady Receives ABC Fredi Kronenberg Excellence in Research and Education in Botanicals for Women’s Health Award

